After Vertex's $10 Billion Crinetics Bet, Why Viking Keeps Rising on Takeover Hopes

Vertex's Crinetics deal reset the takeover bar

Vertex's definitive deal to acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, is anticipated to close in the third quarter of 2026. The bigger signal is simple: major pharmaceutical companies are still paying up for advanced, defensible science.

That does not mean Viking is next. It does mean investors have a clearer read on what large pharma may value now. Vertex is buying commercialized assets, pipeline optionality, and what it described as strong early uptake for PALSONIFY. When a buyer spends at that level, other big companies often start watching similar assets more carefully.

Viking is the harder version of that trade. It has no approved products and essentially no meaningful revenue, so the stock still trades mainly on what VK2735 could become. At the same time, market commentary is already calling it the most closely watched biotech acquisition target. In M&A, perception matters as much as balance-sheet math.

The real question is not whether Viking will be acquired. It is whether Viking continues to look like a strategic asset before the next data milestones.

Viking's VK2735 data makes the takeover case plausible

For an obesity acquisition, buyers do not need a finished label. They need an asset that looks credible, clinically meaningful, and easy to picture on their shelf. On that front, VK2735 is starting to look more like a real commercial asset and less like a lab-stage story.

Early weight-loss numbers are strong enough to matter

In the oral Phase 2 VENTURE-Oral Dosing study, patients achieved body weight reductions of up to 12.2% from baseline after 13 weeks. The earlier injectable Phase 2 program showed up to 14.7% weight loss after 13 weeks. Those figures are not final, but they are large enough to suggest VK2735 has real therapeutic potential rather than just statistical noise.

Maintenance dosing is the more interesting tell

The oral study also included a maintenance cohort in which the weight loss achieved at higher doses was not only maintained but further extended after down-titration to a lower daily dose. For a potential buyer, that is the kind of signal worth paying for: a drug that may help patients keep weight off after the initial drop.

Viking is also moving quickly toward later-stage proof. Its VANQUISH Phase 3 studies of the subcutaneous formulation are fully enrolled, and management expects planned Phase 3 studies with the oral tablet formulation to begin later this year. That gives a buyer a clear sequence of evidence to evaluate.

Cash improves bargaining posture, not the strategic appeal

Viking ended the first quarter with Strong Quarter-End Cash Position of $603 Million. That does not make it a takeover target by itself, but it can strengthen negotiating posture by giving the company more room to wait for the right price.

The main risk is also straightforward: obesity is crowded, and Phase 2 results can underperform in Phase 3. Even so, Vertex's Crinetics deal shows that strategic money is still active. Viking's story stays interesting as long as the next proof points keep the asset looking buyable.

What could turn takeover chatter into a real offer

The market is already treating the idea seriously. Polymarket gives Viking a 38.5% implied probability of being acquired before 2027. That is a sentiment gauge, not proof of a deal. But prolonged interest like that usually points to a broader sense that the asset fits current pharma priorities.

Vertex's own language offers a useful hint. Vertex said Crinetics added assets tied to strong and growing early uptake for PALSONIFY plus pipeline optionality. Applied to Viking, the questions are simpler:

• Does VK2735 show enough efficacy and tolerability to compete in obesity?
• Can Viking keep both the injectable and oral development paths credible?
• Would the asset fit a larger company's metabolic-disease platform in a way that shortens development or broadens commercial reach?

A lower-than-hoped price would not necessarily kill interest. What would change the calculus more is if Viking's upcoming data fail to support the efficacy, tolerability, or development timeline that currently fuels the story.

For now, Viking still looks more like a high-upside watchlist name than a confirmed acquisition story. That is enough to keep the stock tied to takeover speculation, especially after Vertex just put a live price tag on the kind of science big pharma still wants to secure.